TABLE: 2014 IPO values mixed at mid-year
This article was originally published in Scrip
Executive Summary
Going public isn't easy, even in a market that's receptive to biotechnology initial public offerings, but 41 drug developers made the leap in the US during the first half of 2014 and raised $2.6bn.
You may also be interested in...
Cerulean Shifts From Ovarian Cancer To Contraceptives In Reverse Merger With Daré
Cerulean and privately-held Daré entered into a stock purchase agreement that will give the latter company's shareholders a majority stake in the combined company, which will focus on women's health – particularly contraceptives – instead of the former firm's nanoparticle-drug conjugates for cancer.
Cerulean Slashes Jobs After Phase II Kidney Cancer Failure
Cerulean will cut its staff by almost half to reprioritize its remaining cash as it recovers from a clinical trial failure for its lead drug candidate that shifts the program's immediate focus from kidney to ovarian cancer.
Ipsen Expands Its Rare Neurological Disease Pipeline With Skyhawk Deal
Deal Snapshot: Ipsen committed up to $1.8bn in upfront and milestone fees to develop novel treatments for rare neurological diseases with Skyhawk’s RNA-targeting small molecule platform.